A user experienced significant hair regrowth from Xeljanz after severe alopecia but can no longer afford it. They are seeking ways to obtain the medication despite its high cost and potential side effects.
Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The user is seeking advice on adding CB 03-01 to their hair loss treatment, which includes RU58841, Fluridil, Minoxidil, and Pantostin, but cannot use finasteride.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.
Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.
RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.
Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
Cyproterone Acetate stopped hair loss and led to regrowth on the temples for a transgender individual, which is considered a good sign. Unlike Minoxidil and Finasteride, which can cause initial shedding, Cyproterone did not cause shedding.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.